Mehgan Noel Coffey, NP

Mehgan Coffey practices at Kern County Hospital Authority in Bakersfield, California.

Mehgan Coffey's NPI, 1952990194, was assigned on January 12, 2021. Mehgan Coffey holds California license 95016365.

Mehgan Coffey's primary practice is Kern County Hospital Authority, at 1700 Mt Vernon Ave, Bakersfield, CA 93306 in Kern County. The practice phone is (661) 326-2000.

Mehgan Coffey's primary practice is Kern County Hospital Authority in Bakersfield, California. Mehgan Coffey is also affiliated with Kern Medical. The medical group on file is Kern Medical. Dmand AI also links Mehgan Coffey to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mehgan Coffey practices, 2 sites in all. Vendor and product names are available with a free account.

Family is Mehgan Coffey's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Mehgan Coffey is licensed in California.

Dmand AI lists chronic diabetes, diabetic emergency, enlarged thyroid, insomnia, intellectual and developmental disabilities, tobacco use, underactive thyroid and vitamin d deficiency among the conditions Mehgan Coffey treats.

CMS data shows 32 Medicare services from Mehgan Coffey across 2 procedure codes in 2024, all of them office visits, for 30 Medicare patients. Medicare paid $1,612 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 30 Medicare patients who saw Mehgan Coffey in 2024. The largest group is 65 to 74, with 15 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.18, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mehgan Coffey's median patient age at 54, with 59% women.

In 2024, Mehgan Coffey wrote 738 Medicare Part D claims for 73 patients. 85% of them were for generic drugs. CMS names the drug for 524 of them, across 19 drugs with 11 or more claims each, at $27,865 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Mehgan Coffey for performance year 2024, reported as part of a group. Mehgan Coffey accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Mehgan Coffey as offering telehealth.

CMS Open Payments shows 1 general payment to Mehgan Coffey from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Phathom Pharmaceuticals, Inc. paid the most, $10.